Capstone Investment Advisors LLC Takes $203,000 Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Capstone Investment Advisors LLC bought a new stake in Arcus Biosciences, Inc. (NYSE:RCUSFree Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,643 shares of the company’s stock, valued at approximately $203,000.

A number of other hedge funds also recently modified their holdings of the business. Alps Advisors Inc. lifted its holdings in shares of Arcus Biosciences by 2.3% in the third quarter. Alps Advisors Inc. now owns 54,951 shares of the company’s stock valued at $986,000 after purchasing an additional 1,214 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Arcus Biosciences by 10.0% during the third quarter. Arizona State Retirement System now owns 13,530 shares of the company’s stock worth $243,000 after acquiring an additional 1,226 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Arcus Biosciences by 0.4% during the third quarter. Principal Financial Group Inc. now owns 329,442 shares of the company’s stock worth $5,913,000 after acquiring an additional 1,312 shares in the last quarter. GAMMA Investing LLC purchased a new stake in shares of Arcus Biosciences during the fourth quarter worth $31,000. Finally, Teacher Retirement System of Texas raised its holdings in shares of Arcus Biosciences by 13.6% during the third quarter. Teacher Retirement System of Texas now owns 13,496 shares of the company’s stock worth $242,000 after acquiring an additional 1,613 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on RCUS. Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of Arcus Biosciences in a report on Thursday, May 9th. Truist Financial reiterated a “buy” rating and set a $50.00 price objective on shares of Arcus Biosciences in a report on Monday, March 25th. Finally, Citigroup increased their price objective on Arcus Biosciences from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Monday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.50.

Check Out Our Latest Stock Analysis on Arcus Biosciences

Insider Activity

In other news, COO Jennifer Jarrett sold 11,551 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $17.55, for a total value of $202,720.05. Following the sale, the chief operating officer now directly owns 215,253 shares of the company’s stock, valued at $3,777,690.15. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 12.30% of the stock is currently owned by company insiders.

Arcus Biosciences Price Performance

Arcus Biosciences stock opened at $15.81 on Tuesday. Arcus Biosciences, Inc. has a one year low of $12.95 and a one year high of $25.47. The company’s fifty day moving average price is $16.36 and its two-hundred day moving average price is $16.74.

Arcus Biosciences (NYSE:RCUSGet Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.92. The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $28.77 million. Arcus Biosciences had a negative net margin of 97.47% and a negative return on equity of 40.98%. The business’s quarterly revenue was up 480.0% on a year-over-year basis. During the same period in the prior year, the business posted ($1.09) earnings per share. Sell-side analysts anticipate that Arcus Biosciences, Inc. will post -3.02 EPS for the current year.

Arcus Biosciences Company Profile

(Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Featured Articles

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.